Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca Hands LEO Dermatology Potential

Executive Summary

AstraZeneca PLC is handing over two pipeline skin disease medicines, tralokinumab and brodalumab, to LEO Pharma for an upfront payment of $115m while it focuses on other key therapy areas. The UK big pharma has also put an end to its license with Valeant Pharmaceuticals for brodalumab in Europe in favor of its new partner.


Related Content

Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity
2016 Pharma Dealmaking: Waiting On The High-Value Deals
AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline
AstraZeneca’s Business Development Head Grady Outlines Strategy Mix
AstraZeneca Unburdens Itself Of Brodalumab


Related Companies